Fruitflow-II + resVida
Pre-clinicalUNKNOWN 0 views this week 0 watching💤 Quiet
Interest: 12/100
12
Development Stage
1
Pre-clinical2
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Memory Impairment
Conditions
Memory Impairment
Trial Timeline
Jan 1, 2013 → Feb 1, 2016
NCT ID
NCT01766180About Fruitflow-II + resVida
Fruitflow-II + resVida is a pre-clinical stage product being developed by Brain Biotech for Memory Impairment. The current trial status is unknown. This product is registered under clinical trial identifier NCT01766180. Target conditions include Memory Impairment.
What happened to similar drugs?
4 of 4 similar drugs in Memory Impairment were approved
Approved (4) Terminated (0) Active (0)
Hype Score Breakdown
Clinical
3
Activity
4
Company
5
Novelty
0
Community
0
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT01766180 | Pre-clinical | UNKNOWN |
Competing Products
8 competing products in Memory Impairment
| Product | Company | Stage | Hype Score |
|---|---|---|---|
| Donepezil Hydrochloride + Placebo | Eisai | Approved | 43 |
| Roflumilast + Roflumilast placebo + Donepezil + Donepezil placebo + Scopolamine | AstraZeneca | Phase 1 | 29 |
| Aricept + IFN-alpha2A | Pfizer | Phase 2 | 31 |
| Tolterodine ER + Oxybutynin ER | Pfizer | Approved | 43 |
| Levetiracetam, Keppra | UCB | Approved | 43 |
| Piracetam | UCB | Pre-clinical | 26 |
| EGb 761® (Tanakan®) | Ipsen | Approved | 40 |
| LX6171 High Dose + LX6171 Low Dose + Placebo | Lexicon Pharmaceuticals | Phase 2 | 29 |